Related Experiment Video

Updated: May 2, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K

Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: a case series

Fable Zustovich1, Alessandra Ferro1, Patrizia Farina1

  • 1Istituto Oncologico Veneto - IRCCS, Padova, Italy.

Clinical Genitourinary Cancer
|March 4, 2014
PubMed
Abstract

No abstract available in PubMed .

Keywords:
AntiangiogenicCerebralKidneyTarget therapyVEGF

More Related Videos

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

7.4K
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.2K

Related Experiment Videos

Last Updated: May 2, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

7.4K
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K

Articles linked to this work by shared authors, journal, and citation graph.

Census-Based Estimates of Female Genital Mutilation/Cutting Among Foreign-born Women and Girls in Europe.

Studies in family planning·2026

Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable NSCLC: a systematic review and meta-analysis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET study.

Lung cancer (Amsterdam, Netherlands)·2026

Radiomic approach to support multidisciplinary tumor board decision-making in locally advanced non-small cell lung cancer.

Frontiers in oncology·2026

A revised estimation of female genital mutilation/cutting among migrants in Italy for the year 2023.

Journal of biosocial science·2025

Prognostic Value of Preoperative Fibrinogen in Metastatic Clear Cell Renal Cell Carcinoma Patients Undergoing Cytoreductive Nephrectomy.

Clinical genitourinary cancer·2026

Neoadjuvant Surgical Enablement in Renal Cell Carcinoma: Systematic Review and Meta-analysis.

Clinical genitourinary cancer·2026

Severe Cytopenias Following Radioligand Therapy: A Real-World Analysis.

Clinical genitourinary cancer·2026

Growth-Differentiation-Factor 15 (GDF15) and Hepcidin as Prognostic Biomarkers for Abiraterone-Treated Metastatic Castration-Resistant Prostate Cancer.

Clinical genitourinary cancer·2026

The 4-cm Rule in Partial Nephrectomy: Analysis of Surgical Selection and Safety Using Japan's National Clinical Database.

Clinical genitourinary cancer·2026

Time to Partial Nephrectomy Versus Cancer-Specific Mortality in 2 to 4 cm Renal Cell Carcinoma.

Clinical genitourinary cancer·2026

Advances in the LI-RADS Treatment Response Algorithm: Imaging Principles, Diagnostic Challenges, and Clinical Integration Following the LI-RADS 2024 Update.

Cancer management and research·2026

Prevention and management of hormonal crisis in neuroendocrine tumors undergoing PRRT (peptide receptor radionuclide therapy): a systematic review.

ESMO gastrointestinal oncology·2026

Timing of cranial radiotherapy in HER2-positive breast Cancer brain metastases treated with Pyrotinib: a multicentre real-world cohort study.

Clinical and translational radiation oncology·2026

A HALF CENTURY OF PROGRESS IN BREAST CANCER: WHERE DO WE GO NEXT?

Transactions of the American Clinical and Climatological Association·2026

Engineering exosomes-mediated RNA delivery regulates bone homeostasis and alleviates osteoporosis.

Materials today. Bio·2026

EMSCs-derived exosomes rescue p75NTR-/- -mediated osteogenesis deficiency via PI3K/Akt/ERK1/2 signaling pathways.

Materials today. Bio·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us